The recently identified subfamily of WNK protein kinases is characterized by a unique sequence variation in the catalytic domain and four related human WNK genes were identified. Here, we describe the cloning and functional analysis of the human family member WNK2. We show that the depletion of endogenous WNK2 expression by RNA interference in human cervical HeLa cancer cells led to the activation of the extracellular signal-regulated kinase (ERK)1/2 mitogen-activated protein kinases but, in contrast to the depletion of WNK1, had no effect on ERK5. Furthermore, expression of a kinase-dead WNK2-K207M mutant also activated ERK1/ 2 suggesting that WNK2 catalytic activity is required. Depletion of WNK2 expression increased G1/S progression and potentiated the cellular response to low epidermal growth factor concentrations. The molecular mechanism of ERK1/2 activation in WNK2-depleted cells lies downstream of the Raf kinases and involves MEK1 phosphorylation at serine 298 in both HeLa and HT29 colon cancer cells. This modification is linked to the upregulation of MEK1 activity toward ERK1/2. Together, these results provide evidence that WNK2 is involved in the modulation of growth factor-induced cancer cell proliferation through the MEK1/ERK1/2 pathway. The data identify WNK2 as a candidate tumor suppressor gene and suggest a coordinated activity of WNK kinases in the regulation of cell proliferation.
Introduction
Protein kinases are critical components of signal transduction pathways and form a superfamily of around 518 genes in humans (Kostich et al., 2002; Manning et al., 2002) . A recently recognized subfamily, the WNK (with no K ¼ lysine) protein kinases, has attracted much attention, as germline mutations in the WNK1 and WNK4 genes were found to cause pseudohypoaldosteronism type II, a hereditary form of hypertension (Wilson et al., 2001) . WNK kinases are found in multicellular organisms and the human genome contains four related WNK genes . They are unique among protein kinases in lacking the highly conserved catalytic lysine in subdomain II (Hanks and Hunter, 1995) , important for the correct position of adenosine triphosphate (ATP) within the catalytic domain. An alternative lysine residue from subdomain I functionally reconstitutes the active site in WNKs (Xu et al., 2000; Min et al., 2004) , and is part of a characteristic WNK sequence signature .
WNK4 is expressed in the distal nephron and mutations that cause pseudohypoaldosteronism type II affect the regulation of paracellular chloride (Cl À ) permeability as well as the traffic of epithelial ion channels such as the sodium chloride (Na þ -Cl À ) cotransporter (NCCT) and the renal potassium channel ROMK (reviewed in Kahle et al., 2004; Gamba, 2005) . WNK1 has been found to phosphorylate synaptotagmin-2, a protein involved in calcium-dependent membrane fusion during exocytosis and endocytosis , and to activate the protein kinases SGK1 , SPAK and OSR1 (Moriguchi et al., 2005; Vitari et al., 2005; Gagnon et al., 2006) , all of which regulate the activation of various renal ion channels, including the epithelial sodium channel. WNK kinases were further reported to participate in signal transduction pathways related to cell growth and survival. WNK1 was shown to interact with MEKK2 and MEKK3 and act as an upstream activator of the extracellular signal-regulated kinase (ERK)-5 mitogenactivated protein (MAP) kinase pathway . WNK1 also serves as a substrate for protein kinase B/Akt upon the activation of phosphatidyl inositol (PI)-3-kinase (Vitari et al., 2004) and was found to negatively regulate insulin-stimulated mitogenesis in adipocytes (Jiang et al., 2005) . WNK3 was shown to interact with procaspase-3 and its expression levels can modulate the apoptotic/cell survival balance (Verı´ssimo et al., 2006) .
Here, we describe a functional analysis of human WNK2, the yet uncharacterized fourth family member, and demonstrate its role in counteracting ERK1/2 activation and epidermal growth factor (EGF)-mediated G1/S progression in HeLa human cervical cancer cells.
Results

Cloning and expression of human WNK2
We subcloned the human WNK2 cDNA 6894 bp encoding a protein of 2297 amino acids and 243 kDa calculated molecular weight (GenBank accession number AJ242724). Further details on the cloning procedure, on the exon-intron organization and alternative splicing of the WNK2 gene, as well as its homology with the other three WNK kinases are included as Supplementary Information S1-S4. The WNK2 sequence contains the catalytic protein kinase domain at the Nterminal end between residues 195 and 453 (Figure 1a) , Figure 1 Expression and activity of human WNK2. (a) Schematic representation of the WNK2 coding sequence containing 2297 amino acids. Depicted are the protein kinase domain, a coiled coil domain (CC) and three regions of high homology shared with WNK1, WNK3 and WNK4. (b) Northern blot analysis of human WNK2 expression in various human tissues, showing strongest expression in heart and muscle followed by brain and small intestine. (c) Expression of endogenous WNK2 in various human cell lines analysed by reverse transcription-PCR (RT-PCR) (top panels) and western blot (middle panels). For RT-PCR, the respective cloned cDNA ('pcDNA3-WNK2') provided the positive control and reactions without cDNA ('no cDNA') the negative control. For western blots, transfection of Myc-WNK2 into HEK293 cells served as positive control. As loading controls, endogenous RNA polymerase II transcripts (pol II) amplified by RT-PCR or a-tubulin protein levels detected by western blot were used. A western blot analysis of various human tissue extracts revealed WNK2 in brain and muscle (bottom panel). (d) Specificity of the protein band detected by the anti-WNK2 serum. HT29 cells were transfected with either a control small interfering RNA (siGFP) or one of two different WNK2-specific small interfering RNAs (siRNAs) (a and b). At 24 h post-transfection, the expression of WNK2 was analysed by western blot (top panels) and RT-PCR (bottom panels). Note that the detected protein band as well as the WNK2 transcripts was specifically reduced in the presence of both WNK2-specific siRNAs. As internal controls, the amplification of RNA polymerase II transcripts (pol II) or the protein level of a-tubulin was used. (e) In vitro protein kinase activity of immunoprecipitated WNK2. Endogenous WNK2 was immunoprecipitated from HT29 cells (left panels), whereas ectopic WNK2 was isolated from HEK293 cells transfected with either Myc-WNK2, or kinase-dead mutant Myc-WNK2-K207M, or Myc empty vector (EV) (right panels). Cell lysates were prepared, immunoprecipitated with either anti-WNK2 (left panels) or anti-Myc (right panels) antibodies and assayed in the presence of radioactive adenosine triphosphate for autophosphorylation. Proteins were separated by SDS-PAGE, transferred to polyvinylidene fluoride membranes, exposed to an X-ray film and subsequently labelled with either anti-WNK2 (left panel, bottom) or anti-Myc (right panel, bottom) antibodies to document the levels of immunoprecipitated WNK2. (f) Subcellular localization of WNK2. HeLa cells were transfected with GFP-tagged WNK2 and 20 h later analysed by fluorescence microscopy.
WNK2 negatively modulates MEK1/ERK1/2 activation S Moniz et al including the typical WNK kinase signature motif . Except for a C-terminal coiled-coil domain (residues 1931-1959) , the sequence does not reveal any homology to other functional protein domains. The full-length WNK2 sequence also allows assignment of two previously reported cDNAs as incomplete fragments of WNK2, namely, the 'serologically-defined colon cancer antigen 43 0 or NY-CO3 (Scanlan et al., 1998) and the T-cell recognized pancreatic cancer cell antigen P/OKcl13 (Ito et al., 2001) . Northern blot analysis revealed a strong expression of WNK2 in heart and skeletal muscle and a weaker signal in brain and small intestine (Figure 1b) . This is in agreement with the previous data showing that brain, heart, small intestine and colon are the main WNK2-positive tissues by reverse transcription-PCR (RT-PCR) . To identify the relevant experimental models, WNK2 expression was further analysed by RT-PCR in various human cancer cell lines. WNK2 transcript and protein were detected in HT29 (colon), HeLa (cervix carcinoma) and HEK293 (human embryonic kidney) cells, but were absent in SW480 colorectal cells (Figure 1c) . A WNK2-specific antibody was raised against a peptide and did not crossreact with the remaining three WNK family members (see in Supplementary Information S5). This anti-WNK2 serum detected ectopic expression of Myc-WNK2 protein with an apparent molecular weight above 250 kDa in the transfected HEK293 cells. The Myc-WNK2 band co-migrated with an endogenous protein in HT29, HeLa and HEK293 cells (Figure 1c ; middle panels), which could also be detected in human tissue extracts from brain and muscle (Figure 1c ; bottom). The endogenous protein band in HT29 cells was specifically reduced after the transfection with two different WNK2-specific small interfering RNAs (siRNAs), which also depleted the endogenous WNK2 transcripts (Figure 1d ). The protein kinase activity of transfected or endogenous WNK2 was determined by in vitro kinase assays following the immunoprecipitation. These experiments revealed the autophosphorylation of endogenous WNK2 isolated from HT29 cells as well as of overexpressed Myc-WNK2 (Figure 1e) . A kinasedead Myc-WNK2 K207M protein was engineered by the mutation of the catalytic lysine residue that characterizes the WNK kinase family (Xu et al., 2000; Verı´ssimo and Jordan, 2001) . Following the transfection into HEK293 cells, the immunoprecipitated mutant protein revealed a weak but consistent autophosphorylation, indicating that endogenous WNK2 or another protein kinase co-precipitated with the WNK2 mutant protein (Figure 1e ). In agreement with the previous reports showing that myelin basic protein (MBP) is a poor substrate for immunoprecipitated full-length WNK1 kinase (Vitari et al., 2004; Verı´ssimo et al., 2006) , we also observed that immunoprecipitated Myc-WNK2 had no significant kinase activity toward MBP (data not shown), and a suitable WNK2 substrate remained to be identified. The subcellular localization of WNK2 in HeLa cells expressing green fluorescent protein (GFP)-tagged WNK2 was predominantly cytoplasmic (Figure 1f ).
WNK2 expression modulates activation of the ERK1/2 MAP kinase A sequence alignment of the WNK2 catalytic domain with other human protein kinase domains revealed the highest homology scores for MEKK3 (54%) and B-Raf (50%), both involved in the MAP kinase activation. Moreover, WNK1 has previously been shown to activate the ERK5 MAP kinase pathway . We, therefore, compared the effect of WNK2 and WNK1 on the activation of MAP kinases. The expression of WNK2 and WNK1 in HeLa cells was suppressed by specific siRNAs and the levels of activated phosphorylated MAP kinases were analysed by western blot using specific antibodies. As shown in Figure 2a , the WNK1-specific siRNA did not affect WNK2 transcript levels, but reduced WNK1 expression by 55% and inhibited the EGF-induced activation of ERK5, as previously reported . In contrast, the specific suppression of WNK2 had no effect on ERK5 activation (Figure 2a) . Interestingly, the WNK2-specific siRNA remarkably increased the phospho-ERK1/2 signal, whereas the depletion of WNK1 had no significant effect on ERK1/2 activation ( Figure 2b ). In addition, two different WNK2-specific siRNAs reduced WNK2 expression on average by 59% (n ¼ 14) and this increased ERK1/2 activation twofold, with no change in total ERK1/2 (Figure 2c ). In the same cell lysates, the depletion of WNK2 expression had only a marginal effect on the activation of Jun N-terminal kinase (JNK) or p38 MAPK under the same growth conditions (data not shown).
These results suggested that WNK2 and WNK1 are involved in the regulation of two distinct MAP kinase pathways. Whereas WNK1 is required for the activation of ERK5, WNK2 exerts an inhibitory role on the activation of ERK1/2.
WNK2 silencing potentiates the activation of ERK1/2 by EGF in HeLa cells
To further analyse the effect of WNK2 on the ERK1/2 pathway, the kinase-dead K207M mutant was overexpressed in HeLa cells. An increase in the activation of ERK1/2 was observed upon the expression of Myc-WNK2-K207M under the standard growth conditions (Figure 2d ), suggesting that the catalytic activity of WNK2 is required for the negative regulation of ERK1/ 2 activation. Interestingly, WNK2-K207M had no activating effect on ERK1/2 in serum-starved cells. The transfection of wild-type WNK2 had no effect under the standard growth conditions but inhibited ERK1/2 activation following the stimulation with EGF at low concentration ( Figure 2e ).
To test whether WNK2 affected ERK1/2 activation directly, cells were incubated under the conditions that inhibit the ERK cascade. As shown in Figure 3a , growth factor depletion due to serum starvation abolished ERK1/2 activation in the presence of WNK2 siRNAs.
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In addition, the two MEK1/2 inhibitors PD98059 and U0126 prevented any increase in ERK activation following the depletion of WNK2. Our data indicate that WNK2 is not acting directly upon ERK1/2 but rather modulates its upstream stimulus-dependent activation. To further sustain this interpretation, the doseresponse of ERK1/2 activation by EGF was analysed in relation to WNK2 expression levels. Figure 3b shows that depletion of WNK2 in serum-starved cells potentiated about 10-fold the concentration-dependent ERK1/2 activation following EGF stimulation. At higher concentrations of EGF (100 ng/ml), the effect of WNK2 became less pronounced (data not shown). Taken together, our data demonstrate that WNK2 is a negative modulator of the EGF-stimulated ERK1/2 MAP kinase pathway.
WNK2 modulates DNA synthesis and cell proliferation A well-described biological effect of increased ERK1/2 activation is cell cycle progression. To determine whether the depletion of WNK2 and its consequent impact on ERK1/2 activation had indeed a phenotypic relevance, HeLa cells were transfected with control or WNK2-specific siRNAs, grown for 24 h and then pulselabelled for 30 min with bromodeoxyuridine (BrdU) to detect cells in S-phase by immunofluorescence microscopy ( Figure 4a ). As shown in Figure 4b , the average number of cells in S-phase was about 26% in cells transfected with control siRNA. Notably, this percentage increased 1.6-fold to 42.5% in cells treated with WNK2-specific siRNAs. This significant increase in S-phase cells (P ¼ 0.0003) was observed when WNK2 expression was reduced by a mean value of 50% (n ¼ 3) Figure 2 Depletion of endogenous WNK2 activates the extracellular signal-regulated kinase (ERK)-1/2 mitogen-activated protein kinase. (a) HeLa cells were transfected with control (siGFP), WNK2-specific (siWNK2) or WNK1-specifc (siWNK1) small interfering RNAs (siRNAs) and 24 h later analysed by western blot for the activation of ERK5 following the stimulation of cells with 1 ng/ml epidermal growth factor (EGF) for 15 min (top panels). Note that upon suppression of WNK1, but not of WNK2, the phosphorylation of ERK5 by EGF is inhibited. The reverse transcription-PCR (RT-PCR) analysis (bottom panels) shows specificity of the two WNK siRNAs. (b) HeLa cells were transfected with control (siGFP), WNK2-specific (siWNK2) or WNK1-specifc (siWNK1) siRNAs and 24 h later analysed by western blot for the activation of ERK1/2. Note the activation of ERK1/2 upon depletion of WNK2, but not of WNK1 transcripts. (c) Quantification of the activation of ERK1/2 in WNK2-depleted cells. A representative western blot comparing the total ERK1/2 levels with the levels of phosphoT183/Y185 ERK1/2 is shown (top panel). Transfection with either WNK2-specific siWNK2-a or siWNK2-b revealed a mean ERK1/2 activation of about 2.1-fold compared to the control siRNA (middle panel), where the mean residual expression of WNK2 was 41% (bottom panel). Data are presented as the mean7s.d. of seven independent experiments for each siRNA (n ¼ 14). (d) The activation of ERK1/2 was further analysed by comparing the total ERK1/2 with the phospho-T183/Y185 ERK1/2 levels in HeLa cells previously transfected with either the kinase-dead Myc-WNK2 K207M mutant or a control empty vector (EV). Under the standard growth conditions in the presence of serum, WNK2-K207M increased ERK1/2 activation but had no stimulatory effect on serum-starved cells. (e) The activation of ERK1/2 was analysed as described above in HeLa cells overexpressing wild-type Myc-WNK2 or the corresponding control empty vector. In the presence of serum, the overexpression of WNK2 had no effect on ERK1/2 activation but following the stimulation of cells with 0.1 ng/ml EGF for 5 min ERK1/2, activation was inhibited by the presence of Myc-WNK2.
WNK2 negatively modulates MEK1/ERK1/2 activation S Moniz et al ( Figure 4c ). Under these conditions, western blot analysis revealed an increase in the protein level of cyclin D1 (Figure 4b ) and the total cell number increased by 25% (P ¼ 0.027). These data indicate that WNK2-depleted cells passed the G1 restriction point, entered S-phase and then completed the mitosis. The results confirm an inhibitory role of WNK2 on the ERK1/2 MAP kinase activation and downstream cell proliferation.
WNK2 depletion activates the ERK/MAP kinase pathway via phosphorylation of MEK1 at serine 298
To determine which step of the signalling cascade is regulated by WNK2, HeLa cells depleted of WNK2 were analysed for EGF receptor (EGFR) internalization and activation of its downstream components, the Ras GTPase and the kinases B-Raf, Raf-1 and MEK1/2. Following the addition of EGF to cultured HeLa cells, the internalization of the EGF-EGFR complex was followed in a time-course experiment at 371C by immunofluorescence microscopy. No difference in EGF internalization was observed between the cells transfected with control or WNK2-specific siRNAs (see Supplementary Information S6). Next, the guanosine triphosphate (GTP)-bound, activated pool of Ras was analysed. Whereas the stimulation of cells with EGF led to a clear increase in the level of activated Ras, the depletion of WNK2 had no stimulating effect on the cells neither under the standard growth conditions nor after the EGF stimulation. Then, endogenous B-Raf or Raf-1 were immunoprecipitated from siRNA-treated cells and assayed in vitro for their kinase activity using recombinant MEK as substrate. Again, WNK2 depletion had no influence on control or EGF-induced stimulation of B-Raf and Raf-1 (Figures 5b and c) . Importantly and in accordance with our previous results (Figures 2 and 3) , a clear increase in ERK1/2 or MEK1/ 2 activity was detected in the same cell lysates as a result of WNK2 depletion (Figures 5a-c) . Next, the activation of MEK1/2 was analysed using phospho-specific antibodies that recognize phosphorylation of serines 218 and/or 222 in the activation loop as a surrogate measure of MEK1/2 activity (Alessi et al., 1994; Zheng and Guan, 1994) . In four independent experiments, we observed that two different siRNAs (WNK2-a and -b) reduced endogenous WNK2 levels by on average 50% and upregulated about twofold the activation status of MEK1/2 (Figure 5d ) and its immediate downstream target ERK1/2. This indicated that WNK2 affected MEK1/2 activation in a Rafindependent manner. Such a mechanism was previously shown to originate from the phosphorylation of MEK1 at Ser-298. Accordingly, both HeLa and HT29 cells showed increased levels of MEK1 phosphorylation at Ser-298 after WNK2 depletion ( Figure 5e ). As expected, the MEK1 inhibitor U0126 abolished ERK1/2 activation in siWNK2-treated cells, but the phosphorylation status of MEK at Ser-298 was still observed (not shown). Since HT29 colon cancer cells carry an activating B-Raf-V600E mutation (Davies et al., 2002) , the observed increase in MEK1 Ser-298 induced by WNK2 depletion in this model confirms our interpretation that the mechanism involved lies downstream of 
Discussion
The subfamily of WNK protein kinases was recently identified and the human genome encodes four distinct WNK genes. This paper describes the cloning and functional analysis of the yet uncharacterized family member WNK2. As a major finding, we demonstrate that WNK2 negatively regulates the EGF-induced activation of the ERK/MAPK-pathway and the downstream cell cycle progression.
The EGF-induced Ras-Raf-MEK-ERK MAP kinase pathway is evolutionary conserved and controls multiple pathophysiological cellular processes such as proliferation, survival or differentiation. For the regulation of these processes the level of ERK activation in cells plays a critical role and determines the signalling responses to several growth factors and oncogenic pathways. For example, quiescent fibroblasts begin to proliferate following sustained, but not transient, ERK activation (Dobrowolski et al., 1994; Balmanno and Cook, 1999; Murphy et al., 2004) . Moreover, the amplitude of ERK1/2 signalling must be correctly modulated, because if it is too strong, cells will stop cycling and will differentiate or senesce (Marshall, 1995; Sewing et al., 1997; Woods et al., 1997; Kerkhoff and Rapp, 1998) . Therefore, the signalling output depends on a fine tuning of ERK1/2 activity in normal versus transformed cells (Ebisuya et al., 2005) , generating regulatory flexibility of the pathway. For example, scaffold proteins such as Sur-8 (Li et al., 2000) or kinase suppressor of Ras (KSR) recruit cascade components and facilitate signal propagation, thereby potentiating ERK activation (Morrison and Davis, 2003) . In contrast, the depletion of the impedes mitogenic signal propagation (IMP) scaffold protein by siRNAs was found to result in increased and stimulus-dependent MEK activation (Matheny et al., 2004) . Such a threshold modulation was also observed in our experiments, indicating that WNK2 participates in the fine-tuning of ERK1/2 activation as a negative modulator.
In particular, we found that overexpression of WNK2 raised the threshold for ERK1/2 activation in EGFstimulated cells (Figure 2e ), whereas WNK2 depletion rendered cells more sensitive to low concentrations of EGF and increased ERK1/2 activation with subsequent cell cycle progression (Figures 3b and 4) . This effect requires an active WNK2 catalytic domain because the kinase-inactive WNK2 K207M mutant also increased ERK1/2 signalling (Figure 2d ). We show that several signalling components upstream of MEK1 are not involved in the WNK2 molecular mechanism. These include the endocytosis of the EGF receptor, the activation status of GTP-bound Ras and the kinase activity of B-Raf and Raf-1. In contrast, WNK2 depletion increased the phosphorylation levels of MEK1/2 at Ser-218/222, within the conventional Zheng and Guan, 1994) . In addition, an increase in phosphorylation of MEK1 at Ser-298 was observed following the WNK2 silencing. This Ser-298 phosphorylation site in MEK1 is an important point of functional convergence between signalling pathways and has been found to enhance the interaction between MEK1 and Raf-1 (Frost et al., 1997) , to prime MEK1 for its activation by Raf-1 (Coles and Shaw, 2002) or to promote a molecular scaffold containing both MEK1 and ERK1/2 (Eblen et al., 2002) . Recent data also suggest that the phosphorylation of MEK1 at Ser-298 can result in Raf-independent activation of MEK1 through its autophosphorylation at Ser-218 and Ser-222 (Park et al., 2007) . MEK1 can be directly phosphorylated on Ser-298 by protein kinase PAK (Frost et al., 1997; Coles and Shaw, 2002) . This phosphorylation is induced during cellular adhesion to extracellular matrix proteins (Slack-Davis et al., 2003) . This mechanism was shown to potentiate both the amplitude and duration of ERK1/2 activation in response to EGF (Frost et al., 1997) , and was proposed to integrate cell matrix and growth factor signals (SlackDavis et al., 2003) . Thus, WNK2 targets the phosphorylation status of MEK1 at Ser-298 and by counteracting this modification modulates the efficiency with which MEK1 can activate ERK1/2 in response to growth factors. We demonstrated that inhibition of WNK2 released this constraint at MEK1 Ser-298, initiating a more sustained ERK activation. Since this mechanism is dependent on the WNK2 catalytic activity, we assumed that WNK2 may phosphorylate MEK1 directly and interfere with Ser-298 phosphorylation. However, we found no evidence for co-immunoprecipitation between WNK2 and MEK1, and no evidence for phosphorylation of recombinant MEK1 by immunoprecipitated The kinase activity of Raf-1 was determined in the presence or absence of EGF by an in vitro kinase assay using immunoprecipitated endogenous Raf-1 and recombinant kinase-inactive MEK1 as substrate. HeLa cells transfected with a constitutively active Myc-Ras G12V mutant served as a positive control. Note that the Raf-1 kinase activity remains unaffected following the suppression of WNK2, although an increase in MEK1/2 activation is observed in the lysates. (d) Depletion of WNK2 in HeLa cells increases MEK1/2 activation. A representative western blot shows the effect of siWNK2 on the phosphorylation of MEK1/2 at Ser-218/222, a surrogate marker for MEK activity (top panels). The increase in MEK activation (middle) as well as the achieved inhibition of WNK2 expression (bottom) was determined in four independent experiments and the respective mean7s.d. values were graphically displayed (n ¼ 4). (e) Depletion of WNK2 in HeLa (top panels) or HT29 cells (bottom panels) results in the phosphorylation of MEK1 at Ser-298, a modification known to upregulate the activity of MEK1 toward ERK1/2. WNK2 negatively modulates MEK1/ERK1/2 activation S Moniz et al WNK2 in vitro (not shown). Therefore, we speculated that WNK2 acts through another kinase or phosphatase, which regulate the phosphorylation of MEK1 Ser-298. Alternatively, WNK2 may compete with the pathways that regulate PAK activity (Frost et al., 1997) .
The EGF-induced Ras-Raf-MEK-ERK/MAP kinase pathway is frequently activated in human tumors due to various oncogenic mechanisms, including amplification of EGFR genes and activating point mutations in EGFR, Ras or B-Raf (Gschwind et al., 2004; Wellbrock et al., 2004; Rodriguez-Viciana et al., 2005) . It is interesting to note that a partial clone of WNK2 has previously been isolated as the colon cancer antigen SDCC43 (Scanlan et al., 1998) and colon tumors also show frequent hyper-stimulation of the EGFR signalling pathway. Therefore, this oncogenic pathway is considered as an important therapeutic target for anticancer drugs (Sebolt-Leopold and Herrera, 2004) . The design of clinically successful signalling inhibitors of this pathway requires detailed knowledge about the mechanisms involved in fine-tuning of the ERK1/2 activation. In this respect, our data identify WNK2 as a novel fine-tuning signalling factor, which downregulates the intensity of EGFR signalling at the MEK1/ERK level. Conversely, the loss of WNK2 expression may upregulate ERK activation levels so that growth is stimulated and senescence circumvented. These functional properties indicate that WNK2 may function as a tumor suppressor gene. To validate this concept, it will be interesting to determine whether loss-of-function mutations or altered WNK2 expression occurs in patient tumors from tissues where WNK2 is expressed (Verı´s-simo and Jordan, 2001 ). Such molecular defects can be expected to commit premalignant epithelial cells to neoplasia and/or collaborate with other oncogenic defects during the cancer cell progression and survival.
On the basis of our analysis of WNK2, we have further shown that two members of the WNK subfamily act in parallel MAP kinase cascades downstream of the EGFR. WNK1 is an activator of the ERK5 cascade, whereas WNK2 is an inhibitor of the ERK1/2 pathway. Both WNK1 and WNK2 target cell cycle progression and may thus integrate various signals controlling cancer cell proliferation. Indeed, WNK kinases may affect the activity of other WNK family members because in vitro recombinant WNK1 was shown to phosphorylate the catalytic domains of WNK2 and WNK4 (Lenertz et al., 2005) . It will be challenging to elucidate the individual and coordinated activity of WNK kinases in signalling pathways and whether these are integrated with the known role of WNK kinases in regulating ion transport channels.
Note added
While this paper was under revision, a genome-wide scan identified a consistent epigenetic silencing of the WNK2 gene in glioma, indicating a role for WNK2 as a cell growth suppressor (Hong et al., 2007) .
Materials and methods
Cell culture, transfections and RNA interference HeLa (cervix carcinoma) and human embryonic kidney cells HEK293 were maintained in Dulbecco's minimal essential medium (DMEM) and HT29 colon carcinoma cells in RPMI, both supplemented with 10% fetal calf serum (Gibco Invitrogen Corporation, Barcelona, Spain) and regularly checked for the absence of mycoplasma infection. For ectopic expression of plasmid cDNAs, HEK293 cells were transfected at 80-90% confluence using Metafectene (Biontex, Martinsried/Planegg, Germany) and HeLa cells at 60% confluence using LipofectAMINE 2000 (Invitrogen, Barcelona, Spain), both according to the manufacturer's instructions. Transfection efficiencies were determined with a GFP expression vector and found to be 90% for HEK293 and 50% for HeLa cells. Total amounts of transfected plasmid DNA were kept constant at 4 mg per 60 mm dish or 2 mg per 35 mm dish and adjusted with empty vector if required. Cells were analysed after 22 h for biochemical assays or after 16 h for immunofluorescence. Small interfering RNA oligos (siRNAs) were obtained from MWG-Biotech AG (Ebersberg, Germany) and transfected using LipofectAMINE 2000 (Invitrogen), either into HT29 cells at 20% confluence or into HeLa cells at 30% confluence. Transfection efficiencies were estimated using an FITCcoupled siRNA (Qiagen, Hilden, Germany) and were found to be around 70% in HT29 or >90% in HeLa cells. Expression of endogenous WNK2 and WNK1 was inhibited by the transfection of HeLa cells with 200 pmol of siRNA per 35 mm dish or 400 pmol per 60 mm dish, whereas HT29 cells required twice the amount. The targeted sequences were siWNK2-a (5 0 -GCU CGA GGA UGC UGA CAU ATT), siWNK2-b (5 0 -GGA CGC ACC CGA UGA AAU UTT), siWNK1-a (5 0 -GCA GGA GUG UCU AGU UAU ATT) and siWNK1-b (5 0 -AAU UAU GGC UAC GUA UUG ATT). As controls, pre-designed luciferase GL2 siRNA (5 0 -CGU ACG CGG AAU ACU UCG ATT) or a GFP-specific siRNA (5 0 -GGC UAC GUC CAG GAG CGC ACC TT) were used (MWG-Biotech AG). Cells transfected with siRNAs were analysed after 24 h and the achieved reduction in target gene expression was determined in each experiment by removing a 30 ml aliquot from the cell lysate (see below), which was mixed with extraction buffer RLT and RNA extracted as described below.
cDNA cloning and expression plasmids Details on the identification and subcloning strategy of WNK2 are available under S1 in the Supplementary Information file. The nucleotide sequence for the human WNK2 cDNA has been deposited in the GenBank/EBI databank under the accession number AJ242724. The WNK2 cDNA was subcloned as an EcoRI/EcoRV fragment into the pcDNA3-Myc or pEGFP-C2 (Clontech, Mountain View, CA, USA) expression vectors. The kinase-dead WNK2-K207M mutant was obtained using the Quickchange mutagenesis kit (Stratagene, La Jolla, CA, USA). All constructs were verified by automated DNA sequencing. pRK5-Myc-Ras-V12 was a gift from Dr Jonathan Morris (Kings College, London, UK) and pEGFP-B-Raf V600E a gift from Dr Carla Oliveira (IPATIMUP, Porto, Portugal).
Transcript expression analysis and semiquantitative PCR Total RNA was extracted from cell lines or lysates (see below) with the RNAeasy kit (Qiagen) and 1 mg reverse transcribed using random primers (Invitrogen) and Ready-to-Go YouPrime Beads (GE Healthcare, Buckinghamshire, UK). Primers for specific amplification of WNK1 and WNK2 were as described ) and for RNA polymerase II (pol II) were pol II-F (5 0 -GAG CGG GAA TTT GAG CGG ATG C) and pol II-R (5 0 -GAA GGC GTG GGT TGA TGT GGA AGA). Amplification reactions were performed using AmpliTaq polymerase (Perkin-Elmer, Wellesley, MA, USA) in 35 cycles of 941C, 45 s; 601C, 45 s; 721C, 45 s with an initial denaturation of 5 min at 941C and a final extension of 10 min at 721C in the case of WNK2, or in 28 cycles of 941C, 30 s; 641C, 30 s; 721C, 30 s for WNK1 and pol II. These semiquantitative amplification conditions were experimentally determined to correspond to the linear amplification phases. Products were separated on 1.5% Agarose gels and band intensity was quantified using Image J software followed by Pol II normalization. No amplification was obtained when RNA was mock reverse transcribed without adding reverse transcriptase. A multiple tissue northern blot (Clontech) was hybridized using the standard procedures to a radioactively labelled WNK2 probe of 1042 bp corresponding to nucleotides 681-1722 according to the GenBank accession number AJ242724.
Antibodies
A rabbit polyclonal antibody SPT81 was raised and affinitypurified against the synthetic WNK2 peptide 1264 Cell lysis, immunoprecipitation and western blot procedures In all experiments involving the transfection of siRNAs, a nondenaturing cell lysis buffer was used to allow simultaneously for immunoprecipitation and analysis of RNA and protein. Cells were lysed on ice in either 100 ml (35 mm dishes), 250 ml (60 mm dishes) or 750 ml (100 mm dishes) lysis buffer (20 mM Tris-HCl, pH 7.5, 1% NP-40, 130 mM NaCl, 10% glycerol, 10 mM MgCl 2 ) containing 10 mM NaF, 0.1 mM Na 3 VO 4 and 1 mM dithiothreitol (DTT) and a protease inhibitor cocktail was composed of 1 mM phenylmethylsulfonyl fluoride, 1 mM 1,10-phenanthroline, 1 mM EGTA, 10 mM E64 and 10 mg/ml of each aprotinin, leupeptin and pepstatin A (all from SigmaAldrich). For RNA extraction, a 30 ml aliquot was removed and processed as described above. For protein analysis the remaining 70 ml (35 mm dishes) or a 40 ml aliquot (60 mm or 100 mm dishes) was added to 17.5 or 10 ml of 5 Â Laemmli sample buffer, boiled for 10 min and centrifuged at 2500 g for 30 s. In the case of immunoprecipitation experiments, followed or not by kinase assays, the remaining lysate was incubated for 2 h at 41C with the specified antibodies (2.4 mg/ml anti-B-Raf or anti-Raf-1, 48 mg/ml anti-Myc or 26 mg/ml anti-WNK2), then further incubated for 1 h with protein G-Agarose beads (Roche Applied Science) and finally washed three times in cold lysis buffer. For Ras activation assays the lysate was incubated with Raf1 RBD Agarose beads from Cell Biolabs Inc. (San Diego, CA, USA) according to the manufacturer's instructions. Washed beads were directly solubilized in 2 Â SDS sample buffer. Human tissue protein medleys were purchased from Clontech and 50 mg was analysed. All samples were separated in a 10% SDS-PAGE Protean III mini-gels (BioRad, Hercules, CA, USA). Proteins were transferred onto a polyvinylidene fluoride membrane (Bio-Rad) using a Mini Trans-Blot cell (Bio-Rad) at 100 V for 60 min and Coomassiestained to check for equal transfer. Membranes were blocked in Tris-buffered saline, 0.1% Triton X-100, 5% milk powder, probed using the indicated antibodies, then incubated with a secondary peroxidase-conjugated antibody (Bio-Rad) and specific binding detected in a chemiluminescence reaction. For densitometric estimation of protein quantities, the luminescence film exposures from at least three independent experiments were digitalized and analysed using the ImageJ software (NIH).
In vitro kinase assays For in vitro protein kinase assays the beads containing immunoprecipitated kinases were resuspended in 20 ml kinase reaction buffer (30 mM Tris-HCl, pH 7.5, 10% glycerol, 1 mM DTT, 1 mM Na 3 VO 4 , 75 mM MgCl 2 and 500 mM ATP). Assays for WNK2 autophosphorylation activity were performed in the presence of 5 mCi g-[
32 P] ATP and in the presence or absence of 0.75 mg/ml of MBP (Upstate Biotechnologies). Assays for B-Raf or Raf-1 activity were non-radioactive and the endogenous immunoprecipitated Raf kinases were incubated at 301C for 30 min with 200 ng recombinant kinasedead MEK1 protein as substrate (Biosource International, Camarillo, CA, USA). All results were confirmed in at least three independent experiments.
Immunofluorescence microscopy HeLa cells were grown on coverslips, transfected with GFP-WNK2 or Myc-WNK2 and fixed after 16h with 3.7% paraformaldehyde in PBS followed by permeabilization with 0.1% Triton X-100 in PBS. Internalization of the EGF receptor in siRNA-treated cells was determined following the incubation of HeLa cells on ice with 0.4 mg tetramethylrhodamine-labelled EGF (Molecular Probes, Eugene, OR, USA) for 30 min. Cells were then washed twice with cold PBS, transferred to growth medium at 371C and fixed at time 0 or after incubations for 2 or 5 min. Coverslips were mounted on microscope slides with Vectashield (Vector Laboratories, Burlingame, CA, USA); images were recorded on a Zeiss LSM 410 confocal microscope and processed with Adobe Photoshop software.
G 1 /S-progression assay Progression into S-phase was monitored by the incorporation of bromodeoxyuridine (BrdU) as described previously (Matos and Jordan, 2005) . Briefly, HeLa cells were transfected with siRNAs and after 24 h incubated with 60 mM 5-bromo-2-deoxyuridine (BrdU) (Sigma-Aldrich) for 30 min, then fixed with formaldehyde, permeabilized and the DNA denatured by treatment with 4 N HCl. BrdU incorporation was visualized by immunofluorescence with mouse anti-BrdU (Roche Applied Science) followed by goat anti-mouse-TexasRed (Jackson Immunoresearch Laboratories, West Grove, PA, USA), and nuclei were counterstained with 4,6-diamidino-2-phenylindole (DAPI). Fluorescence images of seven randomly chosen fields from different coverslips were digitally recorded on a Zeiss Axiovert 100 fluorescence microscope equipped with a cooled Hamamatsu CCD camera (RGB3-chip). The numbers of BrdU-positive as well as that of total nuclei were counted with a minimum of 1000 cells scored for each transfection and derived from three independent experiments.
